(NASDAQ: SNDX) Syndax Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.65%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 7.68%.
Syndax Pharmaceuticals's revenue in 2023 is $0.On average, 4 Wall Street analysts forecast SNDX's revenue for 2024 to be $3,841,797,091, with the lowest SNDX revenue forecast at $676,628,730, and the highest SNDX revenue forecast at $8,335,291,553. On average, 4 Wall Street analysts forecast SNDX's revenue for 2025 to be $6,430,062,158, with the lowest SNDX revenue forecast at $5,146,445,365, and the highest SNDX revenue forecast at $9,445,363,801.
In 2026, SNDX is forecast to generate $15,846,803,644 in revenue, with the lowest revenue forecast at $12,671,328,465 and the highest revenue forecast at $21,776,636,884.